Stiripentol in Dravet Syndrome
- Conditions
- Dravet Syndrome
- Registration Number
- NCT01533506
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Stiripentol's efficacy in Dravet Syndrome through GABA and glutamate modulation?
How does Stiripentol compare to standard-of-care antiepileptics like clobazam or valproate in reducing seizure frequency in Dravet Syndrome?
Which biomarkers, such as SCN1A mutations or EEG patterns, predict response to Stiripentol in Dravet Syndrome patients with intractable epilepsy?
What are the most common adverse events associated with Stiripentol in Dravet Syndrome and how are they managed in clinical practice?
What combination therapies involving Stiripentol and other antiepileptics (e.g., cannabidiol, fenfluramine) show promise in managing Dravet Syndrome in expanded access programs?
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States
Mayo Clinic in Rochester🇺🇸Rochester, Minnesota, United States